Export Publications

Export the displayed publications:
Number of documents


Patrizia Giannoni

Journal articles18 documents

  • Patrizia Giannoni, Jerome Badaut, Cyril Dargazanli, Alexis Fayd'Herbe de Maudave, Wendy Klement, et al.. The pericyte–glia interface at the blood–brain barrier. Clinical Science, Portland Press, 2018, 132 (3), pp.361-374. ⟨⟩. ⟨10.1042/CS20171634⟩. ⟨hal-02074159⟩
  • Kévin Baranger, Patrizia Giannoni, Stéphane Girard, Sarah Girot, Florence Gaven, et al.. Chronic treatments with a 5-HT4 receptor agonist decrease amyloid pathology in the entorhinal cortex and learning and memory deficits in the 5xFAD mouse model of Alzheimer's disease. Neuropharmacology, Elsevier, 2017, 126, pp.128-141. ⟨10.1016/j.neuropharm.2017.08.031⟩. ⟨hal-01799428⟩
  • Margarita Arango-Lievano, Patrizia Giannoni, Sylvie Claeysen, Nicola Marchi. Longitudinal in vivo imaging of the cerebrovasculature: relevance to CNS diseases. Journal of visualized experiments : JoVE, JoVE, 2016. ⟨hal-01792491⟩
  • Silvia Fossati, Patrizia Giannoni, Maria Solesio, Sarah Cocklin, Erwin Cabrera, et al.. The carbonic anhydrase inhibitor methazolamide prevents amyloid beta-induced mitochondrial dysfunction and caspase activation protecting neuronal and glial cells in vitro and in the mouse brain. Neurobiology of Disease, Elsevier, 2016, 86, pp.29-40. ⟨10.1016/j.nbd.2015.11.006⟩. ⟨hal-01997866⟩
  • Patrizia Giannoni, Margarita Arango-Lievano, Ines das Neves, Marie-Claude ă Rousset, Kévin Baranger, et al.. Cerebrovascular pathology during the progression of experimental ă Alzheimer's disease. Neurobiology of Disease, Elsevier, 2016, 88, pp.107-117. ⟨10.1016/j.nbd.2016.01.001⟩. ⟨hal-01477817⟩
  • Farron Mcintee, Patrizia Giannoni, Steven Blais, George Sommer, Thomas Neubert, et al.. In vivo Differential Brain Clearance and Catabolism of Monomeric and Oligomeric Alzheimer's Aβ protein. Frontiers in Aging Neuroscience, Frontiers, 2016, 8, ⟨10.3389/fnagi.2016.00223⟩. ⟨hal-01705732⟩
  • Sylvie Claeysen, Joël Bockaert, Patrizia Giannoni. Serotonin: a new hope in Alzheimer's disease?. ACS Chemical Neuroscience, American Chemical Society (ACS), 2015. ⟨hal-01792388⟩
  • Christophe Rochais, Cédric Lecoutey, Florence Gaven, Patrizia Giannoni, Katia Hamidouche, et al.. Functioning of the three attentional networks and vigilance in primary insomnia. Sleep Medicine, Elsevier, 2015, 16 (12), pp.1569-1575. ⟨10.1016/j.sleep.2015.06.025⟩. ⟨hal-02191002⟩
  • Christophe Rochais, Cédric Lecoutey, Florence Gaven, Patrizia Giannoni, Katia Hamidouche, et al.. Novel Multitarget-Directed Ligands (MTDLs) with Acetylcholinesterase (AChE) Inhibitory and Serotonergic Subtype 4 Receptor (5-HT 4 R) Agonist Activities As Potential Agents against Alzheimer’s Disease: The Design of Donecopride. Journal of Medicinal Chemistry, American Chemical Society, 2015, 58 (7), pp.3172-3187. ⟨10.1021/acs.jmedchem.5b00115⟩. ⟨hal-02043873⟩
  • Cédric Lecoutey, Damien Hedou, Thomas Freret, Patrizia Giannoni, Florence Gaven, et al.. Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment. Proceedings of the National Academy of Sciences of the United States of America , National Academy of Sciences, 2014, 111 (36), pp.E3825--30. ⟨10.1073/pnas.1410315111⟩. ⟨hal-01800439v2⟩
  • Patrizia Giannoni, Florence Gaven, Dimitri de Bundel, Kevin Baranger, Evelyne Marchetti-Gauthier, et al.. Early administration of RS 67333, a specific 5-HT4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer’s disease. Frontiers in Aging Neuroscience, Frontiers, 2013, 5, ⟨10.3389/fnagi.2013.00096⟩. ⟨hal-01703910⟩
  • Sylvie Claeysen, Patrizia Giannoni. Serotonin type 4 receptor dimers. Methods in Cell Biology, Elsevier, 2013. ⟨hal-01792387⟩
  • Patrizia Giannoni. Alzheimer culprits: cellular crossroads and interplay. Cellular Signalling, Elsevier, 2012. ⟨hal-01792371⟩
  • Patrizio Blandina, Leonardo Munari, Patrizia Giannoni, Chiara Mariottini, Maria Passani. HISTAMINE NEURONAL SYSTEM AS THERAPEUTIC TARGET FOR THE TREATMENT OF COGNITIVE DISORDERS. Future Neurology, Future Medicine, 2010. ⟨hal-01793879⟩
  • Patrizia Giannoni, Maria-Beatrice Passani, Daniele Nosi, Paul L Chazot, Fiona C Shenton, et al.. Heterogeneity of histaminergic neurons in the tuberomammillary nucleus of the rat. European Journal of Neuroscience, Wiley, 2009. ⟨hal-01756945⟩
  • Patrizia Giannoni, Andrew Medhurst, M. Passani, M. Giovannini, C. Ballini, et al.. Regional Differential Effects of the Novel Histamine H3 Receptor Antagonist 6-[(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide hydrochloride (GSK189254) on Histamine Release in the Central Nervous System of Freely Moving Rats. Journal of Pharmacology and Experimental Therapeutics, American Society for Pharmacology and Experimental Therapeutics, 2009, 332 (1), pp.164 - 172. ⟨10.1124/jpet.109.158444⟩. ⟨hal-01764810⟩
  • Maria Beatrice Passani, Corrado Bucherelli, Elisabetta Baldi, Patrizio Blandina, Patrizia Giannoni. Histamine in the brain: Beyond sleep and memory. Biochemical Pharmacology, Elsevier, 2007, 73 (8), pp.1113 - 1122. ⟨10.1016/j.bcp.2006.12.002⟩. ⟨hal-01762502⟩
  • Gabriele Cenni, Patrizio Blandina, Ken Mackie, Daniele Nosi, Lucia Formigli, et al.. Differential effect of cannabinoid agonists and endocannabinoids on histamine release from distinct regions of the rat brain. European Journal of Neuroscience, Wiley, 2006, 24 (6), pp.1633 - 1644. ⟨10.1111/j.1460-9568.2006.05046.x⟩. ⟨hal-01764807⟩

Book sections1 document